Recombinant anti-CD11a humanized monoclonal antibody (Shanghai CP Guojian)

重组抗CD11a人源化单抗（三生国健）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-CD11a humanized monoclonal antibody (Shanghai CP Guojian)
Drug Alias Name重组抗CD11a人源化单克隆抗体注射液（三生国健）CMAB-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeukocyte adhesion glycoprotein LFA-1 alpha antagonists
TargetsLeukocyte adhesion glycoprotein LFA-1 alpha
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A